Clinical predictors of transvenous biphasic defibrillation thresholds.

Transvenous lead systems have become routine for defibrillator placement. However, previous studies of clinical predictors of an adequate nonthoracotomy defibrillation threshold (DFT) evaluated monophasic waveforms or more complex lead systems, including subcutaneous patches. Accordingly, this study is a prospective evaluation of the predictors of an adequate biphasic DFT in 114 consecutive patients undergoing cardioverter-defibrillator implantation with a single transvenous lead. For each subject, 38 parameters were assessed, including standard demographic, electrocardiographic, echocardiographic, and radiographic measurements. An adequate DFT (< or =20 J) was achieved in 92% of patients. Multivariable analysis revealed 2 independent factors predictive of a high threshold: echocardiographic measurements of left ventricular dilation (odds ratio = 0.16, 95% confidence interval 0.05 to 0.53, p = 0.003) and body size (odds ratio = 0.36, 95% confidence interval 0.17 to 0.73; p = 0.005). No patient with a normal left ventricular end-diastolic dimension had a high DFT, whereas 14% (9 of 66) of those with left ventricular dilation had elevated thresholds. When the DFT cutoff was lowered to 15 J, as is necessary with some downsized pulse generators, an adequate threshold was observed in 84% of patients and the same 2 independent predictors of high thresholds were found. These results indicate that an adequate transvenous DFT can be predicted from simple clinical parameters.

Comparison of class Ia/Ib versus class III antiarrhythmic drugs for the suppression of inducible sustained ventricular tachycardia associated with coronary artery disease.

Previous studies suggest that class Ia drugs are ineffective in suppression of sustained ventricular tachycardia by programmed stimulation. More favorable results have been described with combinations of Ia and Ib drugs and also with class III antiarrhythmic drugs, but there have been no direct comparisons between these 2 regimens. The present study was undertaken to compare the electrophysiologic efficacy and predictors of success of these 2 regimens in patients with ischemic heart disease and inducible sustained monomorphic ventricular tachycardia. The population consisted of 136 patients with documented coronary artery disease. All had sustained monomorphic ventricular tachycardia inducible during baseline electrophysiologic study and following intravenous procainamide. Follow-up studies were performed with a combination of oral class Ia and Ib or class III antiarrhythmic drugs. A positive response was the inability to induce a sustained ventricular arrhythmia with up to 3 extrastimuli at 2 right ventricular pacing sites. Response rates were 13% for Ia/Ib combination and 19% for class III agents (p = 0.40). Congestive heart failure differentially affected response rates. Only 8% of those responding to Ia/Ib therapy had heart failure compared with 59% of responders to class III (p <0.01). Multivariate analysis identified heart failure (RR 12.2, p = 0.03) as the only parameter with independent predictive value of response to Ia/Ib therapy. These results indicate that congestive heart failure is a potent predictor of a negative response to a combination of class Ia and Ib antiarrhythmic drugs. In this population, class III drugs or nonpharmacologic therapy should be considered as initial treatment.

Clinical predictors of transvenous defibrillation energy requirements.

Nonthoracotomy and, more recently, transvenous lead systems have become routine for initial implantable cardioverter-defibrillator (ICD) placement. Previous studies of clinical predictors of nonthoracotomy defibrillation energy requirements evaluated multiple complex lead systems that included subcutaneous patches. However, the predictors of an adequate transvenous defibrillation threshold (DFT) have not been assessed previously. Accordingly, the present study is a prospective evaluation of DFT using a uniform testing protocol in 119 consecutive patients undergoing ICD implantation with a single transvenous lead. For each patient, 38 parameters were assessed including standard clinical, echocardiographic, and radiographic measures. An adequate monophasic DFT (< or =20 J) was achieved in 76% of patients. Multivariable analysis revealed 3 independent factors predictive of a high threshold: preoperative amiodarone use (odds ratio = 5.8, p < or =0.002), echocardiographic measures of left ventricular dilation (odds ratio = 0.47, p < or =0.005) and body size (odds ratio = 0.51, p < or =0.006). Patients receiving amiodarone who also had left ventricular dilation constitute a group at considerable (69%) risk for having a high DFT. In contrast, patients with neither of these risk factors have only an 11% chance of having a high threshold. We conclude that an adequate transvenous DFT can be predicted from simple clinical parameters.

Chronic rise in monophasic defibrillation thresholds with a transvenous lead system.

This study was a prospective evaluation of chronic changes of defibrillation thresholds in 31 clinically stable patients with a single transvenous lead, optimal shock polarity, and uniform testing protocol. At a mean follow-up of 273 +/- 146 days, defibrillation thresholds increased 26%, from 13.2 +/- 5.6 J to 17.1 +/- 6:0 J (p < 0.001), and shock impedance increased from 46.2 +/- 7.0 omega to 51.2 +/- 6.2 omega (p < 0.001).

Single-incision and single-element array electrode to lower the defibrillation threshold.

Occasional patients have excessive defibrillation energy requirements despite appropriate transvenous defibrillation lead position and the use of biphasic shocks. A single-element subcutaneous array electrode was implanted in 2 patients with a high defibrillation threshold. The array electrode was implanted through the same infraclavicular incision that was used for implantation of the transvenous lead. The defibrillation threshold decreased from 30 J to 15 J and from 24 J to 9 J with the subcutaneous array electrode.

Short term escape rhythm characteristics after radiofrequency ablation of the atrioventricular junction.

Radiofrequency ablation of the atrioventricular (AV) node has become an established method of treating drug-resistant supraventricular arrhythmias, especially atrial fibrillation. Although it is routine to implant a permanent pacemaker following ablation, one of the potential adverse effects of the procedure is that many patients become pacemaker-dependent and are at risk of an adverse outcome in the event of pacemaker malfunction. Obtaining information about the characteristics of the escape rhythm would be helpful in risk-stratifying these patients and might facilitate modifications of the procedure that would reduce the incidence of this problem. We prospectively studied the clinical parameters and escape rhythm characteristics in 24 patients undergoing radiofrequency ablation of the AV node. Initially, 2 patients had no detectable escape beats and 4 had escape rates <30 beats/min. At 12 hours, 3 of these 4 had adequate (>30 beats/min) escape rates (there were no 12-hour data in 2). The escape rhythm was stable in 17 of the other 18 while 1 had no escape beats at 12 hours. Patients developing right bundle branch block had a greater chance of having an inadequate escape rhythm at 12 hours but this difference was not seen at 24 hours. We conclude that an adequate escape rhythm is usually present immediately after radiofrequency ablation of the AV node and tends to remain stable up to 24 hours. The absence of an escape rhythm immediately after ablation is of limited prognostic value since reliable escape rhythms may emerge subsequently.

Temporary wound covering with a silicon sheet for the soft tissue defect following open fasciotomy. Technical note.

OBJECTIVE: Temporary covering of a defect of the soft tissues with a silicon sheet after fasciotomy in the treatment of compartment syndrome. DESIGN: Retrospective study. SETTING: University Hospital, Tübingen. PATIENTS: From January 1991 to June 1996, open fasciotomy was performed a total of 18 times on 17 patients with compartment syndrome. In 17 of the 18 cases acute vascular ischemia was the cause of the compartment syndrome. INTERVENTIONS: For the 18 necessary fasciotomies, a silicon sheet was temporarily used to cover the defect of the soft tissue temporarily a total of 9 times. The silicon sheet was gradually drawn together and the wound was finally closed with a secondary suture. RESULTS: In 6 of the 9 cases a secondary suture could be performed without any difficulties after the swelling had subsided, and a meshgraft covering was not necessary. Only one patient suffered from wound infection because the silicon sheet had not been sutured correctly. In the other cases there was no sign of infection. The wound dressing was changed painlessly and furthermore, an improved cosmetic result was observed. CONCLUSIONS: There are considerable advantages in the use of a silicon sheet as a temporary covering for the defect of the soft tissues in the treatment of compartment syndrome: lower costs because of shorter hospitalisation and the dressing change is practically painless. A reduced risk of infection and improved cosmetic results are further advantages of this method.

Paradoxical embolism-report of a case involving four organ systems.

Paradoxical embolism through a patent foramen ovale (PFO) can involve multiple organs simultaneously. The most commonly involved sites are the cerebrum and the extremities. Paradoxical embolism to coronary arteries or upper extremities is relatively uncommon. We report a case of acute pulmonary embolism and paradoxical embolism through a patent foramen ovale involving the left upper extremity, brain, and coronary artery. Early diagnosis in the emergency department was made by a trans-esophageal echocardiogram, and the patient was successfully treated with intravenous t-PA and heparin. Patients with acute pulmonary embolism or deep venous thrombosis who also develop signs of systemic embolism should be evaluated for a patent foramen ovale.

Catheter ablation of the slow AV nodal pathway in AV nodal re-entry tachycardia.

AV node re-entry tachycardia has been managed with medical therapy to suppress AV node conduction. Radiofrequency ablation of the slow AV nodal pathway can eliminate recurrent spontaneous AVNRT, while preserving AV node conduction intact.

Distortion of intracardiac electrograms following defibrillator shocks for atrial tachyarrhythmias.

In three patients with a defibrillator system consisting of a Ventak P2 pulse generator and an Endotak C transvenous lead, we observed distortion of intracardiac electrograms following defibrillator shocks for atrial arrhythmias. There was a transient marked widening of the intracardiac ventricular complexes resembling ventricular tachycardia. This phenomenon should be recognized when evaluating arrhythmic episodes.

Percutaneous arterial closure in severely scarred groins: a technical note.

We present a new method to enable the insertion of percutaneous suturing devices in severely scarred groins, using a peel-away sheath. This sheath stabilizes the percutaneous tract for the suturing device. It may help to salvage closure procedures, which would otherwise have to be aborted due to insufficient stiffness of the device shaft.

Effect of a single element subcutaneous array electrode added to a transvenous electrode configuration on the defibrillation field and the defibrillation threshold.

Even with the use of biphasic shocks, up to 5% of patients need an additional subcutaneous lead to obtain a defibrillation safety margin of at least 10 J. The number of patients requiring additional subcutaneous leads may even increase, because recent generation devices have a < 34 J maximum output in order to decrease their size. In 20 consecutive patients, a single element subcutaneous array lead was implanted in addition to a transvenous lead system consisting of a right ventricular (RV) and a vena cava superior lead using a single infraclavicular incision. The RV lead acted as the cathode; the subcutaneous lead and the lead in the subclavian vein acted as the anode. The biphasic defibrillation threshold was determined using a binary search protocol. Patients were randomized as to whether to start them with the transvenous lead configuration or the combination of the transvenous lead and the subcutaneous lead. In addition, a simplified assessment of the defibrillation field was performed by determining the interelectrode area for the transvenous lead only and the transvenous lead in combination with the subcutaneous lead from a biplane chest X ray. The intraoperative defibrillation threshold was reconfirmed after 1 week, after 3 months, and after 12 months. The mean defibrillation threshold with the additional subcutaneous lead was significantly (P = 0.0001) lower (5.7 +/- 2.9 J) than for the transvenous lead system (9.5 +/- 4.6 J). With the subcutaneous lead, the impedance of the high voltage circuit decreased from 48.9 +/- 7.4 omega to 39.2 +/- 5.0 omega. In the frontal plane, the interelectrode area increased by 11.3% +/- 5.5% (P < 0.0001) and in the lateral plane by 29.5% +/- 12.4% (P < 0.0001). The defibrillation threshold did not increase during follow-up. Complications with the subcutaneous electrode were not observed during a follow-up of 15.8 +/- 2 months. The single finger array lead is useful in order to lower the defibrillation threshold and can be used in order to lower the defibrillation threshold.

The quality of autotransfused chest-drainage blood after cardiac surgery: a study of coagulation factors.

A wide range of experience, dating back as far as 1978, has been gained with both the hard-shell cardiotomy reservoir of the heart-lung machine and the Sorensen autotransfusion system as retransfusion systems. Three remains, however, a lack of knowledge regarding the quality of retransfused blood in systems of less complex construction which are already available on the market and involve the use of a pouch (Sentinel-Seal autotransfusion system and Pleur-evac collecting system). The present study entailed the investigation of blood from the chest drainages of twenty patients after cardiac surgery by using a simple retransfusion system (Sentinel-Seal autotransfusion system). In two postoperative groups of patients with low and high blood loss from chest drainage, we determined, in addition to free plasma hemoglobin, the following: factor XII, kallikrein-like activity, thrombin-antithrombin III complex, tissue-plasminogen and d-dimers. In the collective with a low blood loss, we found remarkable cell alterations as well as highly activated and advanced coagulation and an extraordinary fibrinolytic activity. If done at all, retransfusion by the Sentinel-Seal autotransfusion system should be restricted to the first four postoperative hours in cases of high blood loss.

Dietary sodium deficiency potentiates the effect of prostaglandin E2 on in vitro renin release in the rat.

Using a renal cortical slice system from sodium loaded (SL) or sodium deficient (SD) rats, this study investigated whether the effect of prostaglandin E2 (PGE2) on renin release (RR) is mediated by tissue cyclic AMP content (TcAMPc) changes, and if it can be modified by dietary sodium manipulation. At 10(-5) M, PGE2 significantly stimulated RR and TcAMPc in both SL and SD groups of slices. PGE2 doses of 10(-9) M and 10(-7) M were ineffective, although RR, but not TcAMPc, was significantly greater in the SD group in response to 10(-7) M PGE2 than RR in the SL group. Addition of the phosphodiesterase inhibitor theophylline (10(-4) M) together with the same three PGE2 doses maintained the stimulatory effect of 10(-5)M PGE2 alone on RR and TcAMPc in both groups of slices, and reversed the effect of 10(-7) M PGE2 alone on RR and TcAMPc in the SD group of slices only. Added by itself, theophylline was ineffective. These data indicate that: PGE2 can stimulate RR by a direct effect on the juxtaglomerular cells; the RR responses to PGE2 and theophylline administration are enhanced in the SD state; and the possibility of cAMP mediation of the effect of PGE2 on RR is discussed.

Sensing lead failure in implantable defibrillators: a comparison of two commonly used leads.

INTRODUCTION: Despite major technological advances, structural problems in implantable cardioverter defibrillator (ICD) endocardial sensing leads remain a significant problem. There are two types of ICD sensing leads: (1) dedicated bipolar leads and (2) integrated lead systems that include defibrillation coils. The long-term performance of these two lead systems has not been directly compared. METHODS AND RESULTS: We prospectively examined the incidence of lead failure manifested by inappropriate arrhythmia detection in 247 consecutive patients undergoing abdominal ICD implant at a single center between 1991 and 1995. A total of 107 patients received BT-10 (dedicated bipolar) leads and 140 patients received Endotak (integrated bipolar) leads. Over a mean follow-up of 860 +/- 442 days, there were 19 (17.8%) lead failures with the BT-10 lead (261 to 1,505 days postimplant) compared with only 6 (4.3%; P < 0.01) with the Endotak lead (410 to 1,211 days postimplant). Lead failure was due to an insulation defect in all cases, with the problem occurring in the proximal lead (within the pulse generator pocket) in all but one case. Lead survival was significantly better with the Endotak lead (P = 0.015, risk ratio = 3.0, 95% confidence intervals 1.2 to 7.6). CONCLUSION: Late lead failure due to insulation defects in BT-10 sensing leads (causing inappropriate ICD activation) is a relatively common and progressive phenomenon, with difficulties becoming apparent as long as 4 years after implant. This problem is a likely cause of inappropriate shocks in patients with BT-10 leads. Implantation of a new sensing lead should be considered at the time of elective pulse generator replacement, even in the absence of demonstrable oversensing.

Abdominal aortic aneurysms: treatment with juxtarenal placement of covered stent-grafts.

PURPOSE: To determine the technical feasibility and clinical outcome of juxtarenal placement of covered stent-grafts for endovascular treatment of abdominal aortic aneurysms with a proximal neck less than 15 mm long. MATERIALS AND METHODS: In seven patients, abdominal aortic aneurysms with infrarenal necks 3-14 mm long were excluded with juxtarenal implantation of polyester-nitinol coknit stent-grafts. The proximal uncovered portion of the stent-graft (length, 12 mm) was placed across one or both orifices of the renal arteries. Seven patients underwent standard infrarenal stent-graft placement. Clinical outcome in all 14 patients was determined with computed tomography (CT) and laboratory values and also with captopril renography in the patients who underwent juxtarenal placement. The mean follow-up was 10.1 months. RESULTS: Findings from serial follow-up CT and laboratory analysis performed in all patients and captopril renography performed in five of the patients who underwent juxtarenal stent-graft placement did not reveal impaired renal function or perfusion. CONCLUSION: Successful exclusion of abdominal aortic aneurysms located closer than 15 mm to the orifices of the renal arteries is possible with juxtarenal placement of the uncovered portion of the stent in the abdominal portion of the aorta.